GlassScriptPhysician profile
Nathaniel R Whaley
NPI 1245213545
$138,765.37
in general payments reported to CMS, 2019-2025
73 companies · $4,615 in 2025
The $4,615 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $11K · 2021: $25K · 2022: $8,123 · 2023: $4,181 · 2024: $29K · 2025: $4,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $14K · Travel and Lodging: $4,466 · Honoraria: $1,300 · Education: $59.37 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,090.00 |
| Food and Beverage | $13,776.41 |
| Travel and Lodging | $4,465.77 |
| Honoraria | $1,300.00 |
| Education | $59.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $26,724.42 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $19,032.24 | 2021 | |
| Biogen, INC. | $18,357.47 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $14,207.66 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $10,806.54 | 2019-2025 | Ultomiris, Soliris |
| Allergan, INC. | $8,147.24 | 2019-2022 | |
| Genzyme Corporation | $6,940.31 | 2019-2023 | |
| Emd Serono, INC. | $5,470.85 | 2019-2023 | Mavenclad |
| Biohaven Pharmaceutical Holding Company LTD. | $4,826.21 | 2022 | |
| Genentech USA, INC. | $2,874.02 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lundbeck LLC | $2,319.72 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $1,826.95 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,544.26 | 2019-2025 | |
| Abbvie INC. | $1,244.42 | 2019-2025 | Ubrelvy, Duopa, Botox |
| Neurelis, INC. | $1,125.06 | 2020-2025 | Valtoco |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,021.31 | 2019-2025 | Gocovri, Apokyn, Xadago |
| Neurocrine Biosciences, INC. | $828.45 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $691.42 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $688.40 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $668.62 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Amgen INC. | $656.20 | 2019-2025 | Uplizna |
| Supernus Pharmaceuticals, INC. | $637.46 | 2019-2023 | |
| Pfizer INC. | $582.88 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $567.07 | 2019-2025 | Nuplazid |
| Csl Behring | $480.18 | 2019-2025 | Hizentra |
| Tg Therapeutics, INC. | $450.01 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $438.57 | 2022-2023 | Trudhesa |
| Jazz Pharmaceuticals INC. | $412.21 | 2022-2025 | |
| Amylyx Pharmaceuticals, INC. | $400.02 | 2023 | Relyvrio |
| Amneal Pharmaceuticals LLC | $346.08 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Sunovion Pharmaceuticals INC. | $290.53 | 2019-2022 | |
| Greenwich Biosciences, INC. | $274.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $251.25 | 2021-2022 | |
| Grifols USA, LLC | $231.80 | 2019-2025 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $209.81 | 2021-2025 | Acthar |
| Sk Life Science, INC. | $203.31 | 2020-2025 | Xcopri |
| Arbor Pharmaceuticals, INC. | $182.93 | 2019-2022 | |
| Harmony Biosciences LLC | $180.37 | 2020-2024 | Wakix |
| Otsuka America Pharmaceutical, INC. | $178.24 | 2023-2025 | Nuedexta, Rexulti |
| Kyowa Kirin, INC. | $177.95 | 2022-2025 | Nourianz |
| Sumitomo Pharma America, INC. | $171.06 | 2023-2024 | Aptiom |
| Adamas Pharmaceuticals, INC. | $166.18 | 2019-2021 | |
| Celgene Corporation | $164.77 | 2021-2025 | Zeposia |
| Corium, LLC | $141.94 | 2022-2023 | Adlarity |
| Medtronic, INC. | $139.82 | 2024 | Intellis Adaptivestim, Percept PC Brainsense |
| Catalyst Pharmaceuticals, INC. | $131.71 | 2020-2025 | Firdapse |
| Vanda Pharmaceuticals INC. | $125.07 | 2022-2025 | Ponvory |
| Acorda Therapeutics, INC | $123.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.35 | 2024-2025 | Hyqvia |
| Horizon Therapeutics Plc | $97.64 | 2022-2023 | Uplizna |
| Axsome Therapeutics, INC. | $92.34 | 2023-2025 | Sunosi, Symbravo |
| Scilex Pharmaceuticals INC. | $90.74 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $77.83 | 2019-2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $73.20 | 2020-2021 | |
| Zyla Life Sciences, INC. | $69.54 | 2019 | |
| Tanabe Pharma America, INC. | $57.41 | 2021-2024 | |
| Neuropace, INC. | $51.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.58 | 2020-2021 | |
| Impel Pharmaceuticals LLC | $41.60 | 2025 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $41.20 | 2024-2025 | Wainua |
| Mallinckrodt Enterprises LLC | $36.66 | 2019 | |
| Azurity Pharmaceuticals, INC. | $32.36 | 2023 | Horizant |
| Livanova USA, INC. | $28.50 | 2019-2020 | |
| Revance Therapeutics, INC. | $23.92 | 2024 | Daxxify |
| Merz Pharmaceuticals, LLC | $21.44 | 2025 | Xeomin, Inbrija, Ampyra |
| Sandoz INC. | $21.38 | 2024 | |
| Aprecia Pharmaceuticals, LLC | $21.23 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.58 | 2019 | |
| Biodelivery Sciences International, INC. | $16.43 | 2019 | |
| Ge Healthcare | $14.59 | 2025 | |
| Assertio Therapeutics, INC. | $13.63 | 2019 | |
| Almatica Pharma LLC | $11.77 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,072.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Whaley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.